Related Experiment Video
Updated: Apr 18, 2026

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
CaMKII: do not work too hard in the failing heart
Min Liu1, You Li, Ruichuan Chen
1State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, 361101, China.
Insights
Calcium/calmodulin-dependent protein kinase II delta (CaMKIIδ) is elevated in heart disease, driving pathological hypertrophy and heart failure by activating fetal genes. This suggests current heart failure therapies may pose risks.
Area of Science:
- Cardiovascular Biology
- Molecular Pathology
- Gene Regulation
Background:
- Calcium/calmodulin-dependent protein kinase II delta (CaMKIIδ) is implicated in cardiac pathophysiology.
- Distinguishing between pathological hypertrophy and heart failure remains a clinical challenge.
Purpose of the Study:
- To investigate the role of CaMKIIδ in pathological cardiac hypertrophy and heart failure.
- To elucidate the molecular mechanisms by which CaMKIIδ influences cardiac gene expression.
Main Methods:
- Analysis of CaMKIIδ levels in human and mouse heart samples.
- Investigation of CaMKIIδ-mediated histone modification and protein interactions.
- Assessment of CaMKIIδ's role in regulating fetal gene transcription.
Main Results:
- CaMKIIδ levels are increased in both pathological cardiac hypertrophy and heart failure.
- CaMKIIδ phosphorylates histone H3 at serine 10 (H3S10).
- H3S10 phosphorylation recruits 14-3-3 proteins, activating fetal gene transcription.
Conclusions:
- CaMKIIδ is a key mediator linking pathological hypertrophy to heart failure.
- The findings suggest a continuum between these cardiac conditions.
- Current heart failure treatments may carry risks due to CaMKIIδ involvement.
Abstract:
CaMKIIδ, a calcium/calmodulin-dependent protein kinase, plays pivotal roles in the development of heart disease. In this issue of The Journal of Pathology, Salma Awad and colleagues demonstrate that CaMKIIδ is engaged in both pathological hypertrophy and heart failure. By analysis of mouse and human heart samples, they found that the level of CaMKIIδ is increased in both pathological processes. Further studies demonstrated that CaMKIIδ mediates the phosphorylation of histone H3 at serine 10 (H3S10), which then tethers the chaperone protein 14-3-3 to promoter regions of fetal cardiac genes to activate their transcription. Combined with recent highlights on transcription regulation, this study revealed a fuzzy boundary between pathological hypertrophy and subsequent heart failure and indicates that current therapeutic strategies towards heart failure may have potential risks to patients.
More Related Videos
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...

